EXPLAIN Fragile-X: an explorative, longitudinal study on the characterization, treatment pathways, and patient-related outcomes of Fragile X Syndrome by Haessler, F. et al.
Haessler et al. BMC Psychiatry 2013, 13:339
http://www.biomedcentral.com/1471-244X/13/339STUDY PROTOCOL Open AccessEXPLAIN Fragile-X: an explorative, longitudinal
study on the characterization, treatment pathways,
and patient-related outcomes of Fragile X
Syndrome
Frank Haessler1*, Franziska Gaese2, Michael Colla3, Michael Huss4, Christoph Kretschmar5, Marc Brinkman6,
Heike Schieb6, Helmut Peters4, Samuel Elstner7 and David Pittrow8Abstract
Background: Fragile X syndrome (FXS), caused by a mutation of the FMR1 gene on the X chromosome, is the
most common inherited form of intellectual disability and autism spectrum disorders. Comprehensive data are
lacking, however, on the characteristics and management patients with FXS in Germany.
Methods/design: EXPLAIN is a prospective, observational, longitudinal registry with a non-probability sampling
approach. It collects data on patient characteristics, therapeutic interventions, psychosocial parameters (including
those of family members and caregivers), quality of life of caregiver and patient, caregiver burden, and health
economic parameters, such as hospitalisation time. It is designed to include data from 300 patients in ambulatory
care from about 50 centres that employ psychiatrists, paediatricians, neurologists, and other relevant specialists, in
Germany. The study was initiated in March, 2013. Patients will be followed for at least two years.
Discussion: The registry is expected to provide much-needed data on the characteristics and management of
patients with FXS in Germany. It will also allow comparisons with other countries, and will enable gap analyses
based on current guidelines for management of these patients.
Trial registration: The ClinicalTrials.gov identifier is NCT01711606.
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Fragile X syndrome (FXS) is a trinucleotide repeat dis-
order caused by a CGG repeat expansion in the FMR1
gene on the X chromosome (> 200 repeats in the full mu-
tation, compared with 6–54 repeats in the normal popula-
tion). This expanded repeat region causes the loss of the
product fragile X mental retardation protein (FMRP),
which regulates neurotransmitter-activated dendritic tran-
slation and synaptic plasticity [1,2]. FXS constitutes the
most common inherited form of intellectual disability* Correspondence: frank.haessler@med.uni-rostock.de
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reproduction in any medium, provided the or(ID). It is also one of the most well-known genetic mecha-
nisms underlying autism spectrum disorder [3].
Reduced intelligence of varying degrees constitutes a
major symptom of FXS, varying from learning difficulties
to severe cognitive impairment [4]. Speech, language,
and attention deficits, as well as behavioural problems,
frequently occur [5-7]. The incidence of other psycho-
pathological syndromes and disorders is also increased:
about 25- 50% of males with FXS meet full diagnostic cri-
teria for autistic disorder [8-10]. Roughly 15% of children
with FXS suffer from seizures, although these seizures are
relatively benign and resolve upon adulthood [11]. Males
and females are both affected by FXS, but in females
symptoms are often milder, due to the inactivation of one
of the two X chromosomes in female cells.l Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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sample test and DNA analysis by Southern blot or PCR
[12]. Therapeutic options are very limited [13]. In a US
survey, caregivers reported utilisation of medications for
attention deficit disorder, anxiety, hyperactivity, mood
swings, anger, depression, seizures, self-injury, or sleep
disorders [14]. Further, non-drug therapy such as speech-
language therapy or occupational therapy is frequently
administered in this patient group [15].
A number of agents have been tested for a variety of
indications, including FXS, based on their synaptic
mechanisms. These include arbaclofen, RO4917523,
ganaxolone, acamprosate, and minocycline. In addition,
the novel mGluR5 inhibitor AFQ056 (mavoglurant) is
currently being investigated in phase III studies in
adults and children with FXS [16,17].
To date, data on the prevalence and status of patients
with FXS in Germany and other European countries are
limited. Conservative estimations assume that some 20,000
people in Germany suffer from FXS, and that many of
these cases have not yet been diagnosed.
Study aims
Considering this lack of data, we initiated a nationwide
observational registry to document and comprehensively
assess patients with FXS. The registry focuses on soma-
tomedical and neuropsychiatric aspects, cognitive im-
pairment assessment, and quality of life and patient
functioning. Further, economic aspects such as use of
resources are documented. Drug utilization and patient
adherence to therapy are also addressed, for both exist-
ing and new interventions.
Specifically, the registry aims to provide information
on the following aspects of FXS patients and FXS inter-
vention in Germany:
 Characterisation of the phenotype of patients with FXS
 Description of patient characteristics (demographics,
family history, comorbidity, education, employment
status, care and treatment conditions, and insurance
status)
 Documentation of therapeutic interventions and
their outcomes
 Recording and assessment of psychosocial parameters
(including family members and/or caregivers)
 Quality of life of the caregiver and, if possible, the
patient
 Health economic parameters and use of resources
Methods
Design and setting
The present study is a prospective observational study
(registry) in Germany involving physicians from about 50
centres (hospitals and physician practices) experienced inthe management of FXS. Specialists from other disciplines
are also expected to be involved, such as child/adolescent
psychiatrists, general psychiatrists, or physicians in social
paediatric centres. A non-probability sampling method is
used for centres and for patients.
Patients
Inclusion criteria are a confirmed diagnosis of FXS by
genetic testing (> 200 CGG repeats) and written in-
formed consent to participate. No additional genetic
testing is required by this study. Patients of all ages and
both genders are eligible.
Patient data will be collected at baseline and appro-
ximately every 6 months thereafter. Patients will be
followed for at least 2 years.
Parameters
At the inclusion visit, data on the following parameters
will be documented:
 Demographic data (birth year, gender, height, and
weight)
 Availability of prior genetic testing results (to confirm
FXS diagnosis)
 Status/medical history of relatives (FXS status in
siblings, parents, or other family members; selected
comorbidities in father or mother; educational
degree of parents). No information on premutation
in parents is collected.
 Insurance status (statutory health insurance, private
insurance)
 FXS patient history (date of diagnosis and symptoms
at diagnosis as measured by the six-item checklist of
Giangreco et al. [18])
 Information on autistic-like behaviour (using the
checklist by Giangreco et al. [18] that specifies the
characteristics tactile defensiveness, perseverative
speech, hand flapping, and poor eye contact)
 Noteworthy life events in the past six months
(e.g. change of caregiver, relocation, death of
relatives, change of school or workplace)
 Educational status and employment status of the
patient
o Education status (in children/adolescents over
16 years of age)
o Work status (in patients aged ≥ 16 years)
o Pre-school care situation (in children under
6 years of age)
o Education status (in children/adolescents aged
6–17 years)
 Comorbid disorders of the patient (seizures, anxiety,
depression, attention deficit disorder, other)
 Neurologic/psychiatric status (if available, at the
inclusion visit, information from the patient’s charts
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will be recorded)
 Previous and current management of FXS
o medical therapy (in particular, for epilepsy,
anxiety, depression, and/or attention deficit/
hyperactivity disorder, with information on
treatment period and effectiveness of treatment)
o non-drug therapy such as psychotherapy,
ergotherapy, speech-language therapy, physical
therapy, occupational therapy, sociotherapy,
music therapy, etc. (with information on start
date and units per year).
 Symptoms Check List (SCL) [19]
 Economic parameters: contacts by physicians
(various specialties), days of hospitalisation since
suspected FXS diagnosis, absence from work
 Results of psychometric testing
o IQ testing: Adaptives Intelligenz Diagnostikum
(AID) [20], Hamburg-Wechsler-Intelligenztest für
Kinder (HAWIK-R/HAWIE-R) [21], Kaufmann
Assessment Battery for Children (K-ABC) [22],
Snijders Oomen Test [23], or other IQ tests
o Aberrant Behaviour Checklist (ABC Scales) [24]
 Quality of life questionnaires (available as paper
forms in the study file)
o EQ-5D (adults) or EQ-5D-Y (children and
adolescents) [25], to be filled out by patient with
support from caregiver
o Eltern Belastungs Inventar (EBI): German version
of the Parenting Stress Index (PSI) questionnaire,
if caregiver is a family member [26]
o Nurses’ Observation Scale for In-patient
Evaluation (NOSIE), if caregiver is not a family
member [27,28]
o Short version of the International Classification
of Functioning, Disability, and Health (Mini-ICF)
rating for psychiatric disorders [29]
At the follow-up visits (approximately every 6 months),
information on the following parameters will be docu-
mented, in the same manner as at baseline:
 Noteworthy life events (none, change of caregiver,
change of residence, divorce or marital separation of
parents, death of relative, birth of sibling, starting
school, change of workplace, other).
 Educational status and employment status of the
patient
 Current management of FXS (including treatment of
symptoms and concomitant diseases such as
seizures and depression)
o medical therapy
o non-medical therapy
 Economic parameters Results of psychometric testing (as at the baseline
visit)
 Quality of life questionnaires (as at the baseline visit)
Statistical methods
A Statistical Analysis Plan (SAP) was set up prior to ini-
tiation of the registry that specified subgroups for ana-
lysis (e.g. by age group or autism degree according to
physician rating) and statistical methods to be used. The
analysis set will consist of all patients with confirmed
FXS diagnosis included in the study. The observational
study will be analysed descriptively, using established stat-
istical and epidemiological methods. If inferential statistics
such as confidence intervals and/or p-values are calcu-
lated, the results will be regarded as descriptive only. No
adjustments will be made for multiple comparisons.
Continuous variables will be reported as median with
interquartiles and other percentiles, and as mean with
standard deviation (SD), together with minimum and
maximum values. Categorical variables will be reported
as absolute values and relative percentages.
For adverse event (AE) and serious adverse event
(SAE) incidence, rates based on the number of included
patients and incidence density based on the number of
events/ patient years will be calculated. These events, as
well as serious drug reactions, will be presented overall
and by system organ class and preferred term, according
to the Medical Dictionary for Regulatory Activities
(MedDRA) [30].
Our aim is to include 300 ambulatory patients from
about 50 centres in the registry. A minimum sample size
has not yet been determined; it will be determined accord-
ing to feasibility aspects. Interim analyses are planned after
inclusion of 50 and 150 patients. Data will be analysed
with STATA 12.0 (Stata Corporation, College Station,
Texas, USA).
Ethics and applicable laws
This non-interventional study is being conducted in ac-
cordance with the following regulations and guidelines:
(1) codex of the FSA (dated 7 May 2008, BAnz. Nr. 68,
S. 1636); (2) recommendations of the Federal Institute
for Drugs and Medical Products (BfArmM) and the Paul
Ehrlich Institute on the planning, conduct, and analysis
of post-marketing studies, dated 7 July 2010 [31]; (3) rec-
ommendations of the VFA [Association of Research-based
Pharmaceutical Companies, dated 31 Jan 2007 and 23
April 2007) [32]. The study sponsor is Novartis Pharma,
Nürnberg (internal study code CAFQ056BDE-EPI-01),
and the supervising health authority is the BfArM.
The ethics committee of the University of Rostock
approved the study. Patients and caregivers must be
informed about the study and data protection issues
by written patient information, and written informed
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documented.
In 20% of participating centres, on-site monitoring of
the centres will be performed with source data verification.
Physicians will receive remuneration for participation.
Data collection
Data will be entered by designated staff at the centres
via a secure internet-based data entry form. The system
automatically performs completeness and plausibility
checks. Quality of life forms filled out by the patient or
caregiver will be sent to the contract research organisa-
tion (CRO), where they will be entered into the central
database by trained staff. Copies of these forms will re-
main in the patients’ files at the study centres. As data
are collected in pseudonymised form in the database (i.e.
no patient names, initials, or exact birth dates are in-
cluded in the central database), the individual centres
maintain a patient log list that enables them to identify
their patients in the database. Study information will be
archived for at least 10 years by the sponsor, CRO, and
in the individual centres.
Adverse events
Information on adverse events (AE) and serious adverse
events (SAE) related to the administration of any drug
will be collected on standardized forms, regardless of
causality, and will include type of event, occurrence,
duration, and intensity. The investigator is requested to
assess causality and to report actions taken and out-
comes. Information on AE and SAE will be processed by
the study sponsor, Novartis Pharma, in accordance with
established pharmacovigilance rules.
Discussion
Data are incomplete regarding several aspects of FXS,
including epidemiology, clinical and psychosocial char-
acteristics of patients, treatment pathways, and patient-
oriented parameters, including quality of life. To the best
of our knowledge, the only systematic recording of data
takes place in the USA in the context of individual
projects, namely by the Fragile X Clinical & Research
Consortium (FXCRC), with its FORWARD Registry and
Database, and by our Fragile X World Surveys (twice
per year, also supported by the U.S. Centers for Disease
Control) [14,33-35].
Similar data are needed for Europe, including Germany.
The manner and setting of care and specific methods of
management of FXS patients throughout the population
are not clear. This registry will therefore apply a non-
probability approach to collect data on a large sample of
patients (convenience sample). While items and variables
from the FORWARD Registry and Database will be used
to allow comparisons between the registries, a number ofitems which are specific to the German setting have been
added (e.g., setting of care).
For the characterisation of patients and their manage-
ment, available data from the charts will be used. Fur-
ther, patients and their caregivers will be requested to fill
out established and validated questionnaires to assess
the quality of life of patients and caregivers as well as
caregiver burden.
Thus, the registry will provide the basis for a compre-
hensive description of the characteristics and status of
FXS patients in Germany in great detail, will allow for
gap analyses (comparisons with guidelines), and will
likely contribute to the optimisation of management of
this vulnerable patient group in the future.
Trial status
The set-up and testing of the entry form and the database
were finalised at the end of 2012. The study is currently
open for inclusion, and the first patient was included in
March 2013. By the time of this report (14 November
2013), 33 patients have been included. Recruitment is
planned until December 2013, and the field (documenta-
tion) phase of the study will continue until December
2015. An expansion of the registry to countries other than
Germany is also possible. Most study materials are
available in English, with the exception of some assess-
ment forms (e.g., IQ testing using validated German
instruments).
Dissemination of information and publications
The study has been registered in ClinicalTrials.gov
under NCT01711606, and in the VFA database. The ra-
tionale, aims, and design of the study have been previ-
ously presented as posters, e.g., at the 2012 meeting of
the Deutsche Gesellschaft für Psychiatrie, Psychotherapie
und Nervenheilkunde (DGPPN; German Association for
Psychiatry, Psychotherapy, and Neurology). A study report
will be written upon completion of the study. Further, re-
sults will be reported on ClinicalTrials.gov, and the report
will be submitted as a peer-reviewed publication.
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